Efficacy and Safety of Noofen in the Treatment of Chronic Fatigue Syndrome in Patients with Cerebrovascular Failure
Objectives. To assess the efficacy and tolerance of Noofen in the treatment of chronic fatigue syndrome in patients with chronic cerebrovascular failure. Materials and methods. A total of 53 patients with cerebrovascular disease presenting active complaints of feelings of constant fatigue were studied; patients were randomized to form two groups. Patients of the study group (n = 33) received standard treatment and Noofen, while patients of the control group (n = 20) received only standard treatment. Treatment efficacy was assessed using the fatigue evaluation scale MFI-20, the Hospital Anxiety Scale HADS-A, and the Leeds Sleep Evaluation Questionnaire (LSEQ). The effectiveness of mental work was also assessed, using the Schulte test. Results and conclusions. Treatment with Noofen led to a marked decrease in the overall intensity of feelings of fatigue on the MFI-20 fatigue evaluation scale. Regression of fatigue intensity by 30–50% of baseline was seen in three quarters of the patients of the study group, and Noofen influenced reductions in all components of fatigue syndrome, including the mental components, and increased motivation. Reductions in the mental component of fatigue were combined with objective improvements in the effectiveness of mental work on the Schulte test. Thus, the effect of Noofen on the level of motivation and the mental component of fatigue can promote more effective cognitive training in patients with cerebrovascular failure.
Keywordschronic cerebrovascular failure chronic fatigue syndrome anxiety spectrum disorder Noofen
Unable to display preview. Download preview PDF.
- 6.O. V. Vorob’eva and V. V. Rusaya, “Pharmacotherapy of anxiety disorders in patients with chronic cerebral ischemia,” Zh. Nevrol. Psikhiat., 116, No. 12, Iss. 2, 3–8 (2016), https://doi.org/10.17116/jnevro20161161223-8-2017.